Kim Thollund Mortensen

Kim Thollund Mortensen

Auto-generated profile, based on publicly available information

Kim Thollund Mortensen

Department of Chemistry , Technical University of Denmark , DK-2800 Kongens Lyngby , Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in Chemical Reviews
Verified
Journal Article
Closed access
KMKim T. Mortensen
Kim T. Mortensen
TOThomas J. Osberger
Thomas J. Osberger
TKThomas A. King
Thomas A. King
HSHannah F. Sore
Hannah F. Sore
DSDavid Spring
David Spring

28 December 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JFJuly Fong
July Fong
MYMingjun Yuan
Mingjun Yuan
TJTim Holm Jakobsen
Tim Holm Jakobsen
KMKim T. Mortensen
Kim T. Mortensen
MSMay Margarette Salido Delos Santos
May Margarette Salido Delos Santos
MGMichael Givskov
Michael Givskov

7 January 2019 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
JFJuly Fong
July Fong
KMKim T. Mortensen
Kim T. Mortensen
ANAmalie Nørskov
Amalie Nørskov
KQKatrine Qvortrup
Katrine Qvortrup
LYLiang Yang
Liang Yang
MGMichael Givskov
Michael Givskov
Pseudomonas aeruginosa is known as an opportunistic pathogen that often causes persistent infections associated with high level of antibiotic-resistance and biofilms formation. Chemical interference with bacterial cell-to-cell communication, termed quorum sensing (QS), has been recognized as an attractive approach to control infections and address the drug resistance problems currently observed worldwide. Instead of imposing direct selective pressure on bacterial growth, the right bioactive compounds can preferentially block QS-based communication and attenuate cascades of bacterial gene expression and production of virulence factors, thus leading to reduced pathogenicity. Herein, we report on the potential of itaconimides as quorum sensing inhibitors (QSI) of P. aeruginosa. An initial hit was discovered in a screening program of an in-house compound collection, and subsequent structure-activity relationship (SAR) studies provided analogs that could reduce expression of central QS-regulated virulence factors (elastase, rhamnolipid, and pyocyanin), and also successfully lead to the eradication of P. aeruginosa biofilms in combination with tobramycin. Further studies on the cytotoxicity of compounds using murine macrophages indicated no toxicity at common working concentrations, thereby pointing to the potential of these small molecules as promising entities for antimicrobial drug development.

4 June 2018 in ACS Combinatorial Science
Verified
Journal Article
Closed access
RMRemi Jacob Thomsen Mikkelsen
Remi Jacob Thomsen Mikkelsen
KGKatja Egeskov Grier
Katja Egeskov Grier
KMKim Thollund Mortensen
Kim Thollund Mortensen
TNThomas Eiland Nielsen
Thomas Eiland Nielsen
KQKatrine Qvortrup
Katrine Qvortrup

20 January 2020 in Chemical Communications
Verified
Journal Article
Closed access
PDF file
AHAbigail R. Hanby
Abigail R. Hanby
NTNikolaj S. Troelsen
Nikolaj S. Troelsen
TOThomas J. Osberger
Thomas J. Osberger
SKSarah L. Kidd
Sarah L. Kidd
KMKim T. Mortensen
Kim T. Mortensen
DSDavid Spring
David Spring
Herein, we describe the natural product inspired synthesis of 38 complex small molecules based upon 20 unique frameworks suitable for fragment-based screening.

8 July 2019 in European Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
TKThomas A. King
Thomas A. King
HSHannah L. Stewart
Hannah L. Stewart
KMKim T. Mortensen
Kim T. Mortensen
ANAndrew J. P. North
Andrew J. P. North
HSHannah F. Sore
Hannah F. Sore
DSDavid Spring
David Spring
In recent years the pharmaceutical industry has benefited from the advances made in fragment‐based drug discovery (FBDD) with more than 30 fragment‐derived drugs currently marketed or progressing through clinical trials. The success of fragment‐based drug discovery is entirely dependent upon the composition of the fragment screening libraries used. Heterocycles are prevalent within marketed drugs due to the role they play in providing binding interactions; consequently, heterocyclic fragments are important components of FBDD libraries. Current screening libraries are dominated by flat, sp2‐rich compounds, primarily owing to their synthetic tractability, despite the superior physicochemical properties displayed by more three‐dimensional scaffolds. Herein, we report step‐efficient routes to a number of biologically relevant, fragment‐like heterocyclic spirocycles. The use of both electron‐deficient and electron‐rich 2‐atom donors was explored in complexity‐generating [3+2]‐cycloadditions to furnish products in 3 steps from commercially available starting materials. The resulting compounds were primed for further fragment elaboration through the inclusion of synthetic handles from the outset of the syntheses.